EFFICACY OF INJECTION SECUKINUMAB IN ERYTHRODERMIC PSORIASIS

Abstract

Objective: To determine the efficacy of Injection Secukinumab in erythrodermic Psoriasis (EP). Methods: A total of 40 patients having EP were included. Patients with EP who completed the full treatment course of Injection Secukinumab were included.All participants in the study received a 300 mg subcutaneous injection of Secukinumab once a week for five weeks (specifically during weeks 0, 1, 2, 3, and 4). The Psoriasis Area and Severity Index (PASI) was assessed at several intervals, including weeks 0, 4, 8, 12, 16, and 20, alongside monitoring for any adverse drug reactions, patient satisfaction, and the frequency of recurrence. Results: The participants in the study had an average age of 43.75 ± 10.98 years. Out of the 40 participants, there were 16 females (40%) and 24 males (60%). The typical duration for the current episode was approximately 1.24 ± 0.98 months, while the average duration of their disease spanned 3.60 ± 3.58 years. By the 4th week, this score had reduced to 26.63 ± 11.58; at the 8th week, it further declined to 18.17 ± 9.12; by the 12th week, it was at 12.37 ± 7.92; and by the 16th week, the average PASI score reached 10.30 ± 9.40. In terms of treatment effectiveness, there was a marked increase in the percentage of patients who experienced a reduction of 75% or more in their PASI score from the baseline: 10% were noted at the 4th week, 40% at the 8th week, and 70% sustained this improvement from the 12th to the 20th week. Conclusion: Secukinumab therapy is effective in treating patients with EP with minimal side effect profile and acceptable recurrence rates. So Secukinumab can be used as a preferred treatment option in EP patients.